Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Treatment Failure. Found 15 abstracts

Kishan AU, Shaikh T, Wang PC, Reiter RE, Said J, Raghavan G, Nickols NG, Aronson WJ, Sadeghi A, Kamrava M, Demanes DJ, Steinberg ML, Horwitz EM, Kupelian PA, King CR. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Eur Urol. 2017 May;71(5):766-73.
Pollack A, Kwon D, Walker G, Khor LY, Horwitz EM, Buyyounouski MK, Stoyanova R. Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for Prostate Cancer. Journal of the National Cancer Institute. 2017 Feb;109(2):1-8.   PMCID: PMC6075027
Hamstra DA, Bae K, Hanks G, Hu C, Shipley WU, Pan CC, Roach M, Lawton CA, Sandler HM. Impact of Biochemical Failure Classification on Clinical Outcome: A Secondary Analysis of Radiation Therapy Oncology Group 9202 and 9413. Cancer. 2015 Mar;121(6):844-52.   PMCID: 4657945
Turaka A, Li T, Nicolaou N, Lango MN, Burtness B, Horwitz EM, Ridge JA, Feigenberg SJ. Use of a conventional low neck field (LNF) and intensity-modulated radiotherapy (IMRT): no clinical detriment of IMRT to an anterior LNF during the treatment of head-and neck-cancer. Int J Radiat Oncol Biol Phys. 2011 Jan;79(1):65-70.   PMCID: PMC3339153
Buyyounouski MK, Hanlon AL, Horwitz EM, Pollack A. Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. Int J Radiat Oncol Biol Phys. 2008 Jan;70(1):59-66.
D'Ambrosio DJ, Ruth K, Horwitz EM, Chen DY, Pollack A, Buyyounouski MK. Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate cancer?. Urology. 2008 May;71(5):938-41.
Horwitz EM, Levy LB, Thames HD, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA. Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis. Cancer. 2006 Aug 30;107(7):1496-502.
Wong JS, Kaelin CM, Troyan SL, Gadd MA, Gelman R, Lester SC, Schnitt SJ, Sgroi DC, Silver BJ, Harris JR, Smith BL. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol. 2006 Mar;24(7):1031-6.
Hanlon AL, Diratzouian H, Hanks GE. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys. 2002 Jun;53(2):297-303.
Hanks GE, Hanlon AL, Horwitz EM. Evidence for cure of 'young' men with prostate cancer. Oncology (Huntingt). 2001 May;15(5):563-7; discussion 571-4.
Hanlon AL, Pinover WH, Horwitz EM, Hanks GE. Patterns and fate of PSA bouncing following 3D-CRT. Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):845-9.
Horwitz EM, Winter K, Hanks GE, Lawton CA, Russell AH, Machtay M. Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):947-56.
Hanlon AL, Hanks GE. Scrutiny of the ASTRO consensus definition of biochemical failure in irradiated prostate cancer patients demonstrates its usefulness and robustness. American Society for Therapeutic Radiology and Oncology. Int J Radiat Oncol Biol Phys. 2000 Feb;46(3):559-66.
Hanlon AL, Hanks GE. Failure patterns and hazard rates for failure suggest the cure of prostate cancer by external beam radiation. Urology. 2000 May;55(5):725-9.
Keller SM. Current and future therapy for malignant pleural effusion. Chest. 1993 Jan;103(1 Suppl):63S-67S.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Treatment Failure

Treatment Failure Male Prostatic Neoplasms Aged radiotherapy blood 80 and over Aged Prostate-Specific Antigen Middle Aged pathology therapeutic use Human Follow-Up Studies Adult Prognosis mortality Time Factors surgery Middle Age Proportional Hazards Models drug therapy Conformal Radiotherapy Androgen Antagonists methods Treatment Outcome Prospective Studies Multivariate Analysis therapy Disease-Free Survival Neoplasm Staging Combined Modality Therapy Radiotherapy Dosage Hormonal Antineoplastic Agents US Gov't Support-PHS Adenocarcinoma Radiotherapy Comparative Study adverse effects Retrospective Studies Female Transurethral Resection of Prostate Lymph Node Excision Gastrostomy Malignant Pleural Effusion Intensity-Modulated Radiotherapy Brachytherapy Non-Small-Cell Lung Carcinoma Pleura Bladder analysis Analysis of Variance Regression Analysis Linear Models Neoplasm Metastasis Defecation complications Area Under Curve Tumor Suppressor Protein p53 Dose Fractionation Cyclin-Dependent Kinase Inhibitor p16 Sclerosing Solutions Intestines Gleason 10 Local Neoplasm Recurrence Age Factors Head and Neck Neoplasms Chi-Square Distribution epidemiology psychology chemistry Reoperation Reference Values Questionnaires Breast Neoplasms Proto-Oncogene Proteins c-mdm2 utilization Risk ROC Curve Predictive Value of Tests Sclerotherapy Antineoplastic Agents Kaplan-Meier Estimate Radical prostatectomy Psychological Sexual Dysfunctions radiography prostate-specific antigen failure Mammography instrumentation Radiation Dose-Response Relationship Punctures Segmental Mastectomy Lung Neoplasms bcl-2-Associated X Protein diagnosis Adjuvant Chemotherapy secondary Kallikreins Cyclooxygenase 2 Ki-67 Antigen Goserelin physiology Squamous Cell Carcinoma Drainage Incidence Tumor Biomarkers Prostatectomy prevention & control Neoplasm Grading Proto-Oncogene Proteins c-bcl-2 Gleason 9 Intraductal Carcinoma-Noninfiltrating prostate-specific antigen
Last updated on Wednesday, February 05, 2020